A retrospective study evaluating efficacy and safety of sorafenib or lenvatinib combined with sintilimab in patients with advanced hepatocellular carcinoma
Latest Information Update: 20 Jul 2021
At a glance
- Drugs Lenvatinib (Primary) ; Sintilimab (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 20 Jul 2021 New trial record
- 08 Jun 2021 Primary endpoint (Progression-Free Survival (PFS)has not been met.as per Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology
- 08 Jun 2021 Results presented at the 57th Annual Meeting of the American Society of Clinical Oncology